Ad
Thursday, 5 October 2017
Second U.S. jury finds AbbVie misrepresented risks of AndroGel
(Reuters) - A U.S. jury on Thursday ordered AbbVie Inc to pay more than $140 million to a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack, the plaintiff's lawyer said in a statement.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment